---
notetoolbar: Study
share_link: https://share.note.sx/qj0ffiv8#Kliz1zZuyvvWLWOIV6HdoxXX96wZWUGjpGFmv5bXRTo
share_updated: 2024-06-18T19:09:38+08:00
---

> [!scroller] Table of Contents
> ```table-of-contents
> ```

# OVERVIEW OF HEMOSTASIS

## Hemostasis
- A system of checks and balances in which the **blood vascular system**, **platelets**, and **coagulation proteins**, in a series of enzymatic reactions, work together to ensure the fluidity of blood.
- Consists of **primary hemostasis**, **secondary hemostasis** and **fibrinolysis**.

### PRIMARY HEMOSTASIS
#### Blood vessels

|                                                                                                                                                                                                |                                          |
| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------- |
| - **ANTIthrombotic**<br>- Facilitates **blood flow** and **reduces turbulence**                                                                                                                | <mark class="red">INTACT</mark> vessels  |
| - Results to <mark class="red">vasoconstriction</mark><br>- Activation of the **intrinsic pathway due to COLLAGEN EXPOSURE** and **extrinsic pathway due to release of TISSUE THROMBOPLASTIN** | <mark class="red">DAMAGED</mark> vessels |



#### Platelets
- round to oval cells, approximately **2 to 4um** in diameter
- fine purple granules fill the cytoplasm, must be **separated from each other**

> [!NOTE]
> ANucleated cytoplasmic fragments, originated from the megakaryocyte in the bone marrow

- # Phases of Platelet ACTIVATION

|                                                                                                                                                                                                    |                                      |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------ |
| Platelets **adhere to collagen** and undergo change **from discs to spiny spheres**. This is **PRIMARY aggregation** and is <mark class="red">reversible</mark>                                    | <mark class="red">Adhesion</mark>    |
| Platelets **release the contents** of their dense granules and alpha granules. The release of these granules constitutes **secondary aggregation** which is <mark class="red">IRREVERSIBLE</mark>. | <mark class="red">Secretion</mark>   |
| In response to chemical changes, these events lead to **platelet aggregation** in which platelet adhere to other platelets.                                                                        | <mark class="red">Aggregation</mark> |

- # Platelet Cell Surface Receptors

|                                                                |                                                                    |
| -------------------------------------------------------------- | ------------------------------------------------------------------ |
| Receptor for vWF; **adherence to collagen**                    | GP <mark class="red">1b/IX/V complex</mark>                        |
| Fibrinogen receptor; **platelet plug stabilization**           | GP <mark class="red">IIb/IIIa</mark>                               |
| **Collagen receptors**                                         | GP <mark class="red">VI</mark>, GP <mark class="red">Ia/IIa</mark> |
| **Fibronectin receptor**                                       | GP <mark class="red">Ic/IIa complex</mark>                         |
| Adherence of platelets to **negatively charged phospholipids** | GP <mark class="red">Ia/IIa</mark>                                 |

### SECONDARY HEMOSTASIS

- Involves a series of blood protein reactions through a **cascade-like process** that occurs in a **series of four reactions**:
	1. <mark class="red">Initiation</mark>
	2. Activation of <mark class="red">X</mark>
	3. Formation of <mark class="red">thrombin</mark>
	4. Formation of <mark class="red">insoluble fibrin clot</mark>

> [!NOTE]
> ![[Pasted image 20240430163558.png]]
> - describes IN VITRO 


|                                                                                                                                                                                     |                                                      |
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------- |
| - initiated by the release of <mark class="red">tissue factor/Factor III</mark><br>- TF:VIIa complex (convert X to Xa)<br>- Extrinsic Tenase Complex (TF:VIIa complex + Ca2+ + PF3) | <mark class="red">EXtrinsic</mark> cascade<br>       |
| - initiated by <mark class="red">negatively charged phospholipids</mark><br>- Intrinsic Tenase Complex (FIXa + FVIIIa + Ca2+ + PF3)                                                 | <mark class="red">INtrinsic</mark> cascade<br>       |
| (FXa + FVa + Ca2- + PF3)<br>Prothrombin → thrombin                                                                                                                                  | <mark class="red">Prothrombinase complex</mark> <br> |


#### COAGULATION FACTORS

| Factor        | Other Names                                                                                           | Function                                                                                                            | Half-life (hours) | % Activity Required | Pathway   |
| ------------- | ----------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------- | ----------------- | ------------------- | --------- |
| I             | <mark class="red">Fibrinogen</mark>                                                                   | **Thrombin substrate**                                                                                              | 100 - 150         | 30                  | Common    |
| II            | <mark class="red">Prothrombin</mark>                                                                  | Activated **on surface of platelets** by the **PROTHROMBINASE COMPLEX**                                             | 50 - 80           | 30                  | Common    |
| V             | <mark class="red">Labile</mark> factor                                                                | Activated by **THROMBIN**; Va is a **<mark class="red">cofactor</mark> for the activation of PROTHROMBIN** by Xa    | 24                | 20                  | Common    |
| VII           | <mark class="red">Stable</mark> factor                                                                | Activated by **THROMBIN** in the presence of **Ca2+**                                                               | 6                 | 20                  | Extrinsic |
| VIII          | <mark class="red">Anti-hemophilic</mark> factor                                                       | Activated by **THROMBIN**; VIIIa is a **cofactor in the activation of X** by IXa                                    | 12                | 30                  | Intrinsic |
| IX            | <mark class="red">Christmas</mark> factor                                                             | Activated by **XIa** in the **presence of Ca2+**                                                                    | 24                | 30                  | Intrinsic |
| X             | <mark class="red">Stuart-Prower</mark> factor                                                         | Activated on the surface of activated platelets by **TENASE COMPLEX** and by **VII in the presence of TF and Ca2+** | 25 - 60           | 20                  | Common    |
| XI            | <mark class="red">Partial Thromboplastin Antecedent</mark>                                            | Activated by **factor XIIa**                                                                                        | 40 - 80           | 20                  | Intrinsic |
| XII           | <mark class="red">Hagemen</mark> factor<br><mark class="red">Glass</mark> factor (activated by glass) | **Binds to EXPOSED COLLAGEN** at site of vessel injury; activated by **HMWK** and **kallikrein**                    | 50 - 70           | <5                  | Intrinsic |
| XIII          | <mark class="red">Fibrin stabilizing</mark> factor                                                    | **Stabilizes fibrin**                                                                                               | 150               | <5                  | Common    |
| HMWK          | <mark class="red">Fletcher</mark> factor                                                              | Activates **factor XII**                                                                                            | 35                | <5                  | Contact   |
| Prekallikrein | <mark class="red">Fitzgerald</mark> factor                                                            | **Cofactor**; binds to **XIIa** and **prekallikrein**                                                               | 150               | <5                  | Contact   |

^bq7822

|                                                                                                                                                                                                                    |                                               |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------- |
| - Enzyme precursors **II, VII, IX, X, XI, XII, prekallikrein (<mark class="red">2, 7, 9, 10, 11, 12, PK</mark>)**<br>- When **activated become ==SERINE PROTEASES==** (designated by “<mark class="red">a</mark>”) | <mark class="red">Zymogens: proenzymes</mark> |
| - Non-enzymatic V, VIII, HMWK, tissue factor (thromboplastin)<br>- **(<mark class="red">non-enzymatic 5, 8, HMWK, 3</mark>)**                                                                                      | <mark class="red">Co-factors</mark>           |
| - **<mark class="red">prekallikrein</mark>, <mark class="red">kallikrein</mark>, <mark class="red">HMWK</mark>**<br>- Roles include **coagulation activation** and **fibrinolytic activation**                     | <mark class="red">Kinin factors</mark>        |
| - I, V, VIII, XIII **(<mark class="red">1, 5, 8, 13</mark>)**<br>- **Most labile**, consumed in **coagulation**, found on **platelets**                                                                            | <mark class="red">Fibrinogen</mark> group     |
| - II, VII, IX, X **(<mark class="red">2, 7, 9, 10</mark>)**<br>- **Vitamin K <mark class="red">DEPENDENT</mark>**, may be **affected by ==WARFARIN==, ==diet==, ==antibiotics==**                                  | <mark class="red">Prothrombin</mark> group    |
| - XI,XII,HMWK, Prekallikrein **(<mark class="red">11, 12, HMWK, PK</mark>)**<br>- Initiate **intrinsic pathway** and **fibrinolysis**                                                                              | <mark class="red">Contact</mark> group        |

#### CELL-BASED MODEL of Coagulation

> [!NOTE]
> proposed to replace the traditional cascade
> it more accurately explains coagulation <mark class="red">IN VIVO</mark>
> occurs in 3 OVERLAPPING stages

|                                                                                                                                                                                 |                                        |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------- |
| **Vascular endothelium** and **circulating blood cells** are DISRUPTED; interaction of <mark class="red">FVII</mark> with <mark class="red">TF</mark><br>                       | <mark class="red">Initiation</mark>    |
| **Platelets**, FV, FVIII and FXI **(<mark class="red">5, 8, 11</mark>)** are **activated by ==THROMBIN==** on the platelet's surface<br>                                        | <mark class="red">Amplification</mark> |
| Results in **production of an adequate amount of thrombin activity**, **production of temporary plug** at the site of injury and **stops the interruption of blood supply**<br> | <mark class="red">Propagation</mark>   |


### FIBRINOLYSIS

> [!NOTE]
> regulatory mechanism of coagulation cascade
> ![[Pasted image 20240430164906.png]]

|                                                                                                                                                                   |                                          |
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------- |
| Becomes **bound to fibrin** at the time of fibrin polymerization                                                                                                  | **<mark class="red">Plasminogen</mark>** |
| - Serine protease that systematically **digests fibrin**<br>- Also **digests FV, FVIII and fibrinogen (5, 8, 1)**<br><br>- MAIN ENZYME of the fibrinolytic system | **<mark class="red">Plasmin</mark>**     |


# DISORDERS OF HEMOSTASIS

## QUANtitative Disorders of Primary Hemostasis
| Feature                | <mark class="red">Acute ITP</mark>                                                                        | <mark class="red">Chronic ITP</mark>                                           |
| ---------------------- | --------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------ |
| Peak age               | **Children**                                                                                              | **Adults**                                                                     |
| Initial platelet count | **<20** x 10⁹/L                                                                                           | **<30-80** x 10⁹/L                                                             |
| Onset                  | **Abrupt**                                                                                                | **Insidious**                                                                  |
| Antecedent infection   | **Common**                                                                                                | Unusual                                                                        |
| Spontaneous remission  | **Common**                                                                                                | Rare                                                                           |
| Therapy #table-column  | <mark class="red">Corticosteroids</mark>, <mark class="red">anti-D</mark>, <mark class="red">IV Ig</mark> | <mark class="red">Corticosteroids</mark>, <mark class="red">Splenectomy</mark> |

^mvgojk

> [!NOTE] ITP (Immune Thrombocytopenic Purpura)
> - one of the most common disorders causing SEVERED ISOLATED thrombocytoPENIA
> - destruction of platelets (immune-mediated)
> - impaired platelet production (immune)
> - <mark class="red">IgG</mark> directed to GP <mark class="red">IIb/IIIa</mark>, GP <mark class="red">Ib/IX</mark>, GP <mark class="red">V</mark>

### Distinguishing Features Between TTP and HUS

> [!NOTE] TTP (Thrombotic Thrombocytopenic Purpura)
> - deficiency of ADAMTS-13 (necessary to form a cleaving protease responsible for digesting large vWF multimers)
> - presence of <mark class="red">large vWF multimers</mark>
> - Congenital form: <mark class="red">Upshaw-schulman Syndrome</mark> ^3h8lj2

> [!NOTE] HUS (Hemolytic Uremic Syndrome)
> - deficiency in proteins that regulate the alternative pathway
> - common in CHILDREN (95%)
> - ADULT onset: caused by bacterial infections (<mark class="red">EHEC O157:H7</mark>), <mark class="red">connect tissue</mark> disease, some times of <mark class="red">cancer</mark> ^nmqdtm

| <mark class="red">Thrombotic Thrombocytopenic Purpura</mark>                                                                                                                                                               | <mark class="red">Hemolytic Uremic Syndrome</mark>                                                                                                                 |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| Adults: <mark class="red">20 - 50 yo</mark>                                                                                                                                                                                | Children: <mark class="red">less 5 yo</mark>                                                                                                                       |
| <mark class="red">Pentad</mark><br>- **Hemolytic anemia with RBC fragmentation**<br>- **Renal dysfunction**<br>-  **Thrombocytopenia**<br>- **Severe CNS symptoms**<br>- **<mark class="red">Fever</mark>** #table-column  | <mark class="red">Tetrad</mark><br>- **Hemolytic anemia with RBC fragmentation**<br>- **Acute renal failure**<br>- **Thrombocytopenia**<br>- **Mild CNS symptoms** |

^ix8hvr


## QUALitative Disorders of Platelets
https://youtu.be/-hpU1-TMlEI?t=3258



| Defect                                                              | Disorder type                      | Disease                                                           | Cause/Remarks                                                          |
| ------------------------------------------------------------------- | ---------------------------------- | ----------------------------------------------------------------- | ---------------------------------------------------------------------- |
| <mark class="red">Platelet-vessel wall interaction</mark>           | <mark class="red">Inherited</mark> | <mark class="red">Von Willebrand disease</mark>                   | ↓ vWF or defect in vWF                                                 |
| ^                                                                   | ^                                  | <mark class="red">Bernard-Soulier syndrome</mark>                 | defect in GP Ib/IX/V complex                                           |
| ^                                                                   | <mark class="red">Acquired</mark>  | <mark class="red">Paraproteinemia</mark>                          | ↑ IgA & IgM (coating platelets)                                        |
| <mark class="red">Platelet-platelet aggregation interaction</mark>  | <mark class="red">Inherited</mark> | <mark class="red">Afibrinogenemia</mark>                          | ↓ plasma fibrinogen                                                    |
| ^                                                                   | ^                                  | <mark class="red">Glanzmann thrombasthenia</mark>                 | defect in GP IIb/IIIa                                                  |
| ^                                                                   | <mark class="red">Acquired</mark>  | <mark class="red">Dysfibrinogenemia</mark>                        |                                                                        |
| <mark class="red">Platelet secretion and signal transduction</mark> | <mark class="red">Inherited</mark> | <mark class="red">Storage pool disorders</mark>                   | Abnormal platelet aggregation                                          |
| ^                                                                   | ^                                  | <mark class="red">Alpha-granule deficiency</mark>                 | Gray platelet syndrome (abnormalities of platelet granules)            |
| ^                                                                   | ^                                  | <mark class="red">Dense-granule deficiency</mark>                 | Chediak-Higashi<br>Hermansky Pudlak                                    |
| ^                                                                   | <mark class="red">Acquired</mark>  | <mark class="red">Aspirin</mark>, <mark class="red">NSAIDs</mark> | inhibit the CYCLOOXYGENASE (needed to convert arachidonic acid → TXA2) |

^0fb2m5

### Types of von Willebrand Disease

> [!NOTE]
> most common of the CONGENITAL BLEEDING disorders

> [!NOTE] ALGORITHM
> - Family history
> 	- bleeding from trauma
> 	- excessive bruising
> 	- menorrhagia
> - Laboratory Evaluation 
> 	- FVIII activity
> 	- VWF antigen
> 	- VWF:Ristocetin cofactor
> - if initial lab evaluation normal,
> 	- test for other bleeding disorders
> 	- repeat initial testing in a few weeks
> - if lab eval ABNORMAL
> 	- RIPA aggregation
> 	- Collagen binding
> 	- → multimer analysis
> 
> ![[Pasted image 20240513080722.png]]
> ```mermaid
> graph TD
> 
> B -.-> D(Abnormal)
> D -.-> E(RIPA aggregation)
> D -.-> F(Collagen binding)
> E -.-> G(Multimer analysis)
> F -.-> G
> 
> subgraph A[Family History]
> H(bleeding from trauma)
> I(excessive bruising)
> J(menorrhagia)
> end
> 
> subgraph B[Laboratory evaluation]
> K(F8 activity)
> L(vWF antigen)
> M(vWF:Ristocetin cofactor)
> end
> 
> subgraph C[Normal]
> N(test for other bleeding disorders)
> O(repeat initial testing in a few weeks)
> end
> 
> A -.-> B
> B -.-> C
> 
> ```

| TYPE                                                                                              | <mark class="red">Ristocetin cofactor</mark> | <mark class="red">vWF Antigen</mark> | <mark class="red">Rco:vWF</mark> | <mark class="red">FVIII Activity</mark> | <mark class="red">RIPA</mark> | <mark class="red">Platelet count</mark> | <mark class="red">Multimer pattern</mark> |
| ------------------------------------------------------------------------------------------------- | -------------------------------------------- | ------------------------------------ | -------------------------------- | --------------------------------------- | ----------------------------- | --------------------------------------- | ----------------------------------------- |
| <mark class="red">1</mark> <br>(70-80% cases)                                                     | ↓                                            | ↓                                    | N                                | ↓ or N                                  | ↓ or N                        | N                                       | Normal distribution                       |
| <mark class="red">2A</mark>                                                                       | ↓                                            | ↓                                    | ↓                                | ↓ or N                                  | ↓ or N                        | N                                       | ↓ HMW                                     |
| <mark class="red">2B</mark>                                                                       | ↓                                            | ↓                                    | N or ↓                           | ↓ or N                                  | ↑ w/ low dose                 | ↓                                       | ↓ HMW                                     |
| <mark class="red">Platelet type</mark> (PSEUDO vWF dss)<br><br>(increased affinity of plt to vWF) | ↓                                            | ↓                                    | N                                | N                                       | ↑ w/ low dose                 | ↓                                       | ↓ HMW                                     |
| <mark class="red">2N</mark><br><br>(mimicking Hemophilia A)                                       | ↓ or N                                       | ↓ or N                               | N                                | ↓                                       | N                             | N                                       | Normal                                    |
| <mark class="red">2M</mark>                                                                       | ↓                                            | ↓                                    | ↓                                | ↓ or N                                  | ↓ or N                        | N                                       | Normal                                    |
| <mark class="red">3<br></mark><br>                                                                | ↓↓                                           | ↓↓                                   | N                                | ↓↓                                      | ↓                             | N                                       | absent multimers                          |

^mmxl09

> [!NOTE]
> 1 & 3 (quaL)
> 2 (quaN)

> [!NOTE]
> vWF (produced by platelets & endothelial cells; stored in Weibel-Palade bodies)

## PLATELET AGGREGATION STUDIES


> [!NOTE] Title
> ![[Pasted image 20240430170853.png]]
> (initial wave) due to platelet shape change
> (primary aggregation) reversible
> (secondary aggregation) due to release of internal ADP -  component of dense granules; IRREVERSIBLE

> [!NOTE]
> Sample (PRP); must be tested w/in 4 hours
> NO aspirin intake 7-10 days BEFORE the test

> [!NOTE] https://youtu.be/-hpU1-TMlEI?t=4707
> ![[Pasted image 20240513082257.png]]

### Interpretation of Platelet Aggregometry Results

> [!NOTE]
> take note of X and Y axis

|                                      |                                                                                                                                                                                                                                                                               |
| ------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| ![[Pasted image 20240430170942.png]] | N = ECA; **Abn = Ristocetin**<br><br><mark class="red">von Willebrand dss</mark><br><mark class="red">Bernard-Soulier syndrome</mark><br>-  Giant platelet syndrome<br>-  ↑ GP Ib/IX/V complex                                                                                |
| ![[Pasted image 20240430170952.png]] | **Abn = ECA**; N = Ristocetin<br><br><mark class="red">Afibrinogenemia</mark><br><mark class="red">Glanzmann's thrombasthenia</mark><br>-  ↓ GP IIb/IIIa<br>-  decrease expression of CD41 & CD61                                                                             |
| ![[Pasted image 20240430171002.png]] | **Partial = ADP & epi**<br>**Abn = Collagen**<br>N = Ristocetin<br><br>Storage Pool Disorders<br>-  <mark class="red">Chediak- Higashi</mark><br>-  <mark class="red">Hermansky- Pudlak</mark><br>-  <mark class="red">Wiskott-Aldrich</mark><br><br>Defective TXA2 synthesis |

> [!NOTE]
> - Chediak-Higashi
> 	-  albinism, recurrent infections, lysosomal granules (+)
> 	- defect in dense granules
> - Hermanski-Pudlak
> 	- triad
> 	- tyrosinase-positive oculocutaneous albinism
> 	- accumulation of ceroid-like pigment in macrophages
> 	- bleeding tendency
> - Wiskott-Aldrich (prob in BOTH alpha & dense granules)
> 	- triad
> 	- thrombocytopenia
> 	- recurrent infections
> 	- eczema

> [!NOTE]
> Dense granules (Ca2+, ADP, Pyrophosphates, ATP, serotonin)

## Disorders of Secondary Hemostasis
| Disease/Deficiency                                                          | Laboratory Finding                                          | Remarks                                                                                                                         |
| --------------------------------------------------------------------------- | ----------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Afibrinogenemia</mark>                                    | NO FIBRINOGEN<br>**Prolonged PT, aPTT and TT**              | Umbilical stump bleeding, easy bruising, ecchymoses, poor wound healing, hematuria                                              |
| <mark class="red">Hypofibrinogenemia</mark>                                 | Low fibrinogen<br>**Prolonged PT, aPTT and TT**             | mild bleeding                                                                                                                   |
| <mark class="red">Dysfibrinogenemia</mark>                                  | Normal fibrinogen antigen<br>With **low activity**          | possible hemorrhage, thrombosis, asymptomatic                                                                                   |
| <mark class="red">Hypoprothrombinemia</mark>                                | **Prolonged PT and aPTT**                                   | post-operative bleeding, epistaxis, menorrhagia, easy bruising                                                                  |
| <mark class="red">Parahemophilia</mark> (prob: f5)                          | **Prolonged PT, aPTT and BT**                               | Epistaxis, menorrhagia, easy bruising                                                                                           |
| <mark class="red">Hypoproconvertinemia</mark> (prob: F7)                    | **Prolonged PT**, normal aPTT                               | Epistaxis, menorrhagia, cerebral hemorrhage                                                                                     |
| <mark class="red">Hemophilia A</mark> (prob: F8; sex-linked)                | Normal PT, BT and platelet function, **prolong aPTT**       | Mild, moderate, severe bleeding tendencies                                                                                      |
| <mark class="red">vWF</mark>                                                | Normal PT, **variable aPTT and BT**                         | ^                                                                                                                               |
| <mark class="red">Hemophilia B</mark> (prob: F9; sex-linked)                | Normal PT, **prolonged aPTT**                               | ^                                                                                                                               |
| <mark class="red">Stuart-Prower deficiency</mark> (prob: F10)               | **Prolonged PT and aPTT**                                   | Menorrhagia, bruising, epistaxis, CNS bleeding                                                                                  |
| <mark class="red">Hemophilia C</mark> (prob: F11, AUTOsomal; Rosenthal dss) | Normal PT, **prolonged aPTT**                               | Mild bleeding, bruising, epistaxis                                                                                              |
| <mark class="red">Hageman trait</mark> (prob: F12)                          | Normal PT, **prolonged aPTT**                               | Thrombotic tendency, NO BLEEDING                                                                                                |
| <mark class="red">Factor XIII deficiency</mark>                             | Normal PT and aPTT<br>**Abnormal 5M Urea solubility assay** | same finding w/ afibrinogenemia <br>+<br>excessive fibrinolysis, male sterility, difficulty conceiving, intracranial hemorrhage |
| <mark class="red">Prekallikrein</mark>                                      | Normal PT, **prolonged aPTT**                               | Thrombotic tendency, NO BLEEDING                                                                                                |
| <mark class="red">HMWK</mark>                                               | Normal PT, **prolonged aPTT**                               | ^                                                                                                                               |

^jtwrv7

## EVALUATION OF SECONDARY BLEEDING DISORDERS

```leaflet
id: mixing-studies
image: [[Pasted image 20240430171519.png]]
defaultZoom: 9
width: 80%
```



> [!NOTE]
> PT (Extrinsic)
> APTT (INtrinsic)
> ↑PT, N APTT (Extrinsic)
> N PT, ↑ APTT (INtrinsic)
> ↑PT, ↑ APTT (Common)

> [!NOTE]
> at least 50% coag factors = NORMAL


|                                          | FOUND                                                     | NOT FOUND               |
| ---------------------------------------- | --------------------------------------------------------- | ----------------------- |
| <mark class="red">Aged serum</mark>      | XI, XII, PK, HMWK (Contact)<br>X, IX, VII (PT grp)        | I, V, VIII, XIII, II    |
| <mark class="red">Adsorbed plasma</mark> | XI, XII, PK, HMWK (Contact)<br>I, V, VIII, XIII (Fib grp) | II, VII, IX, X (PT grp) |

^eo8t55

## Factor VIII inhibitor
<mark class="red">Factor VIII (8) inhibitor</mark> is found in **==10%–20% of hemophilia patients== receiving REPLACEMENT THERAPY**. It may also develop in patients with **immunologic problems**, **women after childbirth**, and patients with **lymphoproliferative and plasma cell disorders**, or it may develop **in response to medications**. Factor VIII inhibitor is **an ==IgG immunoglobulin== with an inhibitory effect that is TIME and TEMPERATURE DEPENDENT**. The presence of factor VIII inhibitor causes an **elevated APTT** in the face of a **normal prothrombin time**. The APTT would **NOT BE CORRECTED by mixing studies** if **<mark class="red">LUPUS ANTICOAGULANT</mark> was present**. In addition, lupus anticoagulant is **NOT ASSOCIATED with bleeding** unless it coexists with thrombocytopenia.

> [!NOTE]
> F8 inhibitor
> APTT↑, immediate mixing (corrected); incubated mixing ↑

> [!NOTE] Lupus anticoagulant
> Lupus Anticoagulant associated with THROMBOSIS (in VIVO)
> Lupus anticoagulant (in VITRO)
> APTT↑, immediate mixing (not corrected)

## Thrombophilia

> [!NOTE]
> abnormal tendency toward EXCESSIVE thrombosis

| #table-column | <mark class="red">Arterial</mark> Thrombosis<br><br>- myocardial infarction                                                | <mark class="red">Venous</mark> Thrombosis<br><br>- deep vein thrombosis                                                                                                                                    |
| ------------- | -------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Common        | - **Antiphospholipid syndrome** <br> - **Prothrombin mutation** <br> - **HIT (Heparin-induced thrombocytoPENIA) syndrome** | - **Factor V Leiden mutation** <br> - **Prothrombin mutation** <br> - **Antiphospholipid syndrome** <br> - **Protein C deficiency** <br> - **Protein S deficiency** <br> - **AT (Antithrombin) deficiency** |
| Rare          | - **Elevated PAI1 (Plasminogen activator inhibitor) activity** <br> - **Hyperhomocysteinemia**                             | - **Hyperhomocysteinemia** (homocysteine promotes clot formation) <br> - **Heparin cofactor II**                                                                                                            |
| Also consider | - **Anomalous coronary arteries** <br> - **Vasculitis**                                                                    | - **Immobilization** <br> - **Trauma** <br> - **Pregnancy**                                                                                                                                                 |

^h7tqpm

## INHIBITORS OF COAGULATION

| Name                                                                                                                                               | Mechanism                                                                                                                                      |
| -------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Protein C</mark>                                                                                                                 | Degrades factor **Va** and **VIIIa** (5a, 8a); targets Vitamin K DEPENDENT factors (↓ protein C values in cases of warfarin OVERDOSE )         |
| <mark class="red">Protein S</mark>                                                                                                                 | Degrades factor **Va** and **VIIIa** (5a, 8a)<br>Cofactor of Protein C                                                                         |
| <mark class="red">Anti-thrombin III</mark>                                                                                                         | **Major inhibitor of thrombin**, also inhibits factors IXa, Xa, Xia. XIIa, kallikrein and plasmin **(9a, 10a, 11a, 12a, kallikrein, plasmin)** |
| <mark class="red">Heparin cofactor II</mark>                                                                                                       | **Inhibits thrombin**                                                                                                                          |
| <mark class="red">α2-macroglobulin</mark>                                                                                                          | Forms a **complex with ==thrombin==, ==kallikrein== and ==plasmin==**                                                                          |
| **EPI (<mark class="red">extrinsic pathway inhibitor</mark>)**<br>**LACI (<mark class="red">lipoprotein associated coagulation inhibitor</mark>)** | **Inhibits the ==VIIa-tissue factor complex==**                                                                                                |
| <mark class="red">C1 inhibitor</mark>                                                                                                              | **Inactivator of factor XIIa (==12a==) and ==kallikrein==**, it also **inhibits factor Xia (==11a==) and ==plasmin==**                         |
| <mark class="red">α1 antitrypsin</mark>                                                                                                            | **Inhibitor of ==thrombin==, Xa (==10a==) and XIa (==11a==)**                                                                                  |

# LABORATORY EVALUATION OF HEMOSTASIS

## TESTS FOR DIFFERENTIAL DIAGNOSIS OF ABNORMAL COAGULATION

|                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| -------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| <mark class="red">Prothrombin time</mark>                      | Useful screening procedure for the **EXTRINSIC coagulation** (F7)<br><br>target of **WARFARIN therapy monitoring**<br>Procedure: <mark class="red">PPP</mark> (15k rpm, 15 minutes) + Pt reagent (<mark class="red">Thromboplastin</mark> + <mark class="red">CaCl2</mark>)<br><br>NV: <mark class="red">10 - 12 seconds</mark><br><br>INR                                                                                                                   |
| <mark class="red">Activated Partial Thromboplastin Time</mark> | Most useful procedure for routine screening of coagulation disorders in the **INTRINSIC pathway**. For detecting the **presence of ==circulating anticoagulants (inhibitors)==**, and **monitoring ==HEPARIN therapy==**<br><br>Phospholipid (aka Partial Thromboplastin) + Activator + CaCl<br><br>Activators (Kaolin, Celite, Ellagic acid, Micronized silica)<br><br>NV: <mark class="red">20 - 45 seconds</mark><br>Timing STARTS upon addition of CaCl2 |
| <mark class="red">Stypven Time</mark>                          | Used to detect deficiencies in prothrombin, fibrinogen and factor V and X **(1, 2, 5, 10)**<br><br>differentiate F7 vs F10 def (prolong)<br><br><mark class="red">Russels viper venom</mark> (powerful coagulant)<br><br>NV: <mark class="red">6 - 10 secs</mark>                                                                                                                                                                                            |
| <mark class="red">Thrombin Time</mark>                         | Measures the availability of **functional fibrinogen.**<br><br>NV: <mark class="red">10 - 14 secs</mark><br><br>affected by HEPARIN contamination                                                                                                                                                                                                                                                                                                            |
| <mark class="red">Reptilase time</mark>                        | Helpful in testing for **functional fibrinogen** when the **thrombin time is PROLONGED because of heparin.**<br><br>uses <mark class="red">Bothrops atrox snake venom</mark> -  Thrombin-LIKE activity<br><br>NOT affected by HEPARIN contamination                                                                                                                                                                                                          |
| <mark class="red">5M urea solubility test</mark>               | Factor XIII deficiency **(13) screening test**<br><br>NO PROLONGATION IN PT, APTT<br><br>aka <mark class="red">Duckert's test</mark><br><br>NV: <mark class="red">insoluble clot</mark><br><br>**slow wound healing**                                                                                                                                                                                                                                        |
| <mark class="red">DRVVT</mark>                                 | Often helpful for the **detection of <mark class="red">LUPUS ANTICOAGULANT</mark>**<br><br>In VIVO - thrombotic agent; neutralize = HEPARIN<br>In VITRO - anticoagulant; neutralize = PLATELETS<br>                                                                                                                                                                                                                                                          |


|                                                   | Thrombin time | Reptilase time |
| ------------------------------------------------- | ------------- | -------------- |
| <mark class="red">Heparin therapy</mark>          | ↑             | N              |
| <mark class="red">Fibrin Split products</mark>    | ↑             | ↑              |
| <mark class="red">HYPOfibrinogenemia</mark>       | ↑↑↑           | ↑              |
| <mark class="red">DYSfibrinogenemia</mark>        | ↑             | ↑↑↑            |
| <mark class="red">Immunologic antithrombin</mark> | ↑             | N              |

^yxvqrj

## THOMBOELASTROGRAPHY

> [!NOTE]
> - holistic unlike coagulation asays
> - measures the interaction of platelets with the coagulation cascade
> - aggregation, clot strengthening, fibrin cross-linking & fibrinolysis
> - represents the cell based model of hemostasis (initiation, amplification & propagation phase)





|                                                 |                                                                                                                                                    |
| ----------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------- |
| R = <mark class="red">reaction time</mark>      | = latency until clot formation begins as defined by an amplitude of 2mm<br>NV: <mark class="red">3 - 9 minutes</mark>                              |
| K = <mark class="red">K value</mark>            | = time from the end of R until the clot reaches 20mm<br>- reflects speed of initial clot formation<br>NV: <mark class="red">0.5 - 3 minutes</mark> |
| a = <mark class="red">a angle</mark>            | = angle tangent to the curve of K<br>NV = <mark class="red">54 - 80 degrees</mark>                                                                 |
| MA = <mark class="red">maximum amplitude</mark> | = reflects total clot strength<br>NV: <mark class="red">51 - 78mm</mark>                                                                           |
| LY30 = <mark class="red">lysis time</mark>      |  = % lysis after 30 minutes<br>- reflects the fibrinolysis stage of clot development                                                               |

![[Pasted image 20240430174033.png]]

### Interpretation of Thromboelastography Patterns


| Patterns                             | Reading                                                                               | Cause                                                                                               |
| ------------------------------------ | ------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------- |
| ![[Pasted image 20240430174130.png]] | Normal                                                                                |                                                                                                     |
| ![[Pasted image 20240430174149.png]] | R = prolonged<br>K = prolonged<br>a = decreased<br>MA = decreased                     | delayed clot formation<br><br>presence of <mark class="red">Anticoagulants/Factor deficiency</mark> |
| ![[Pasted image 20240430174159.png]] | R = normal<br>K = prolonged<br>a = normal<br>MA = decreased                           | decreased clot strength<br><br><mark class="red">Platelet blockers</mark>                           |
| ![[Pasted image 20240430174210.png]] | R = normal<br>MA = decreased<br>LY30 = markdly increased                              | accelerated clot breakdown<br><br><mark class="red">increased Fibrinolysis</mark>                   |
| ![[Pasted image 20240430174228.png]] | R = decreased<br>K = shortened<br>a = increased<br>MA = increased                     | accelerated clot formation<br><br><mark class="red">HYPERcoagulable state</mark>                    |
| ![[Pasted image 20240430174239.png]] | R = decreased<br>K = shortened<br>a = increased<br>MA = increased<br>LY30 = increased | accelerated clot formation & breakdown<br><br><mark class="red">Early DIC</mark>                    |
| ![[Pasted image 20240430174321.png]] | R= prolonged<br>K = prolonged<br>a = decreased<br>MA = decreased                      | <mark class="red">Late DIC</mark>                                                                   |
